Merck presents sac-TMT results. Merck & Co. stock gains 1.93 percent.

Published on 10/29/2026 at 11:31 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

TroFuse-005 cut death risk 32.00 percent on October 26, 2026. Merck & Co. stock costs EUR 128.60, 1.93 percent above the Xetra close.

TroFuse results and FDA review

TroFuse-005 extended median overall survival by 6.9 months on October 26, 2026.
Median progression-free survival reached 7.2 months versus 3.9 months for physician's choice.
Merck & Co. stock was trading at EUR 128.60 at 11:22 a.m. CET at Lang & Schwarz on October 29, 2026, 1.93 percent above the Xetra close of October 28, 2026.
The FDA set June 15, 2027, as the target action date for sac-TMT.

Merck & Co., US58933Y1055, Illustration mit AI erstellt.

Merck & Co. (ISIN US58933Y1055) was trading at EUR 128.60 at Lang & Schwarz on October 29, 2026, at 11:22 a.m. CET, 1.93 percent above the Xetra close of October 28, 2026, at EUR 126.16. The company announced on October 26, 2026, that its investigational cancer drug sacituzumab tirumotecan reduced the risk of death by 32.00 percent in the Phase 3 TroFuse-005 trial, according to Merck.com.

Trial results strengthen the pipeline

The trial evaluated sac-TMT against physician's choice of doxorubicin or paclitaxel in patients with advanced or recurrent endometrial cancer who had already received platinum-based chemotherapy and anti-PD-1 or PD-L1 treatment. With a median follow-up of 14.0 months, median overall survival was 19.0 months with sac-TMT versus 12.1 months with physician's choice.

Progression-free survival also improved to 7.2 months from 3.9 months, while the objective response rate was 35.1 percent versus 17.3 percent. Merck said the results were presented at the European Society for Medical Oncology Congress 2026 and published simultaneously in The Lancet.

What happens after the review?

The U.S. Food and Drug Administration accepted Merck's biologics license application for priority review based on the trial. The agency set June 15, 2027, as the Prescription Drug User Fee Act target action date. The application concerns adults with endometrial cancer previously treated with platinum chemotherapy and a PD-1 or PD-L1 inhibitor.

The regulatory timetable gives the oncology pipeline a concrete milestone beyond Merck's established products. The release also said the TroFuse program contains 18 ongoing global Phase 3 trials across multiple tumor types, although the broader program remains subject to clinical and regulatory outcomes.

Stock and company details

Merck's latest reported second-quarter 2026 revenue was USD 16.61 billion, according to the company's investor-relations materials. That figure provides a recent operating reference while the market weighs pipeline progress against the commercial risks surrounding future product launches.

Merck & Co. stock was trading at EUR 128.60 at Lang & Schwarz on October 29, 2026, at 11:22 a.m. CET, 1.93 percent above the Xetra close of October 28, 2026, at EUR 126.16. The further course of trading is shown by the continuously updated real-time quote of Merck & Co stock.